Disrupting organ transplantation with whole, AI-guided, unlimited livers

Khufu (koo-foo): Building livers the way Khufu built the Great Pyramid — with precision, at scale, and built to last.

Khufu Therapeutics employs human stem cells and in vivo manufacturing to grow personalized or allogeneic full-scale livers in just two months.

Founder Dr. Natesh Parashurama, MD PhD, an MIT-, Harvard-, Stanford-, and UCSF-trained surgeon and bioengineer, spent nearly two decades uncovering the cellular and developmental mechanisms that allow the liver to grow and repair itself. His vision was simple yet transformative: to rebuild the liver from within.

This vision led to the creation of our proprietary platform to grow personalized (i-liver) and allogeneic (a-liver) organs. Our platform integrates synthetic biology, organ engineering, and AI-driven computational modeling to regenerate functional liver tissue directly inside the body.

There is no limit to the number of livers we can grow — eliminating the transplant wait-list lottery for patients and delivering new, rejuvenated livers that transplantation alone cannot guarantee.

We are revolutionizing how the world approaches organ failure, starting with the liver.

ABOUT

THE PROBLEM

Cirrhosis is a global epidemic hiding in plain sight.

Over 4 million Americans and 100 million people worldwide are living with end-stage liver disease, yet fewer than 0.25% receive a transplant each year. Every other patient is left to manage symptoms while their liver slowly fails.

Unlike other organs, the liver cannot be replaced or supported by machines or drugs. Once cirrhosis sets in, the organ’s architecture collapses—hepatocytes die, scar tissue replaces healthy tissue, and function disappears.

For 20 years, major pharmaceutical and biotech companies have tried and failed to reverse cirrhosis:

Drugs target inflammation or fibrosis but cannot rebuild lost tissue.
Devices and bioreactors provide only temporary support.
Transplants are scarce, costly, and require lifelong immunosuppression.
iPSC-hepatocyte and 3D-printed approaches fall short in restoring full liver mass or function.

The result is a devastating human and financial toll: millions dying without options, billions spent on palliative care, and no scalable cure in sight.